5 High Growth Micro-cap Stocks to Buy

2. Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)

Latest QTR YoY Revenue Growth: 62.5%

Number of Hedge Fund Holders: 15

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) is an Illinois-based company that was established after Xeris Pharmaceuticals, Inc. acquired Strongbridge Biopharma plc in 2021. The company is involved in the development of novel technology platforms for developing and commercializing stable injectable and infusible drug formulations.

On November 9, Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) announced its third-quarter earnings with a GAAP EPS of -$0.09, topping the analysts’ estimates by $0.03. The revenue grew 62.5% YoY to $48.32 million, surpassing the estimates by $7.24 million.

On November 13, H.C. Wainwright lowered the price target on Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)’s stock to $5.50 from $6 and maintained a Buy rating on the shares.

According to Insider Monkey’s database, hedge fund sentiment was positive toward Xeris Biopharma Holdings, Inc. (NASDAQ:XERS). In the third quarter, 15 hedge funds were bullish on the stock, compared to 11 funds in the previous quarter. Timothy P. Lynch’s Stonepine Capital owned 5.9 million company shares worth $11 million, making it the top investor in the company.

Follow Xeris Biopharma Holdings Inc.